Celldex Therapeutics, Inc.
CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receā¦ read more
Healthcare
Biotechnology
38 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$25.50
Price+2.25%
$0.56
1Y
Price
Market Cap
$1.693b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-25534.0%
EBITDA Margin-21030.8%
Net Profit Margin-26270.5%
Free Cash Flow MarginRevenue
$7.559m
-11.8%
1y CAGR+43.6%
3y CAGR+23.4%
5y CAGREarnings
-$178.851m
-2.4%
1y CAGR-30.6%
3y CAGR-27.4%
5y CAGREPS
-$2.72
+2.4%
1y CAGR-22.9%
3y CAGR-12.5%
5y CAGRBook Value
$702.981m
$739.471m
Assets$36.490m
Liabilities$3.428m
DebtDebt to Assets
0.5%
-
Debt to EBITDAFree Cash Flow
-$171.924m
-10.8%
1y CAGR-28.0%
3y CAGR-33.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company